Forum Markets Inc (FRMM) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
No case yet. It builds on the next filing, report or 13F period.
Forum Markets Inc has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 6199, Finance Services, from each company's own filings. Largest first.
Forum Markets Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Finance Services
High 4.80 at 7:45 am ET, low 4.52 at 1:45 pm ET.
tall tick = annual report · 1 on record
FRMM (Forum Markets Inc) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
40 managers report a position worth $49.0M between them, and 7 of them hold 80% of it.